Having a limited SBIR-STTR presence and that sometime ago, Shoreline Biome, LLC is structured around development of next generation sequencing (NGS) test for micro-biome environment . The firm's work organizes around identifying pathogenic changes from multiple microbial sources that could adversely affect hospitalized individuals. The firm's initial product: a DNA sequencing assay rapidly, inexpensively, and precisely to identify constituents of the microbiome at the species and potentially subspecies level from complex samples such as fecal material. The combination of speed, ease of use, and Next-Generation Sequencing throughput from this test could allow researchers to profile up to 96 microbiomes at once at high resolution.The human microbiome -- beneficial microbes living in and on the body -- plays a key role in maintaining health by regulating immune system, helping to digest food, and defending from pathogens. Disruption in the human microbiome is now demonstrated as the direct cause of diseases like C. difficile, a major global health priority, and is suspected as a causative factor in chronic ailments including allergy, obesity, immune system deregulation, and mental health. Shoreline Biome was founded to be at the leading edge of discovery in understanding how the human microbiome functions across the entire landscape of human health and disease.
